Physician profile
Alejandro Rocha
NPI 1528028099
$10,328.06
in general payments reported to CMS, 2019-2025
44 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $1,728 · 2021: $1,797 · 2022: $995 · 2023: $1,274 · 2024: $1,737 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.33 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,429.61 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $1,136.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $902.69 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Astellas Pharma US INC | $844.36 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $782.89 | 2019-2025 | |
| Lilly USA, LLC | $739.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $510.10 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.75 | 2020-2025 | Xifaxan |
| Novo Nordisk INC | $405.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $369.11 | 2019-2024 | Xarelto, Spravato |
| Phathom Pharmaceuticals, INC. | $299.25 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.39 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $243.76 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $192.99 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $185.59 | 2019-2025 | Rexulti |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $139.23 | 2019-2025 | Verquvo, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $123.29 | 2020-2023 | Livalo, Seglentis |
| Horizon Therapeutics Plc | $118.70 | 2021-2022 | |
| Exact Sciences Corporation | $110.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $86.85 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $80.27 | 2019-2021 | |
| Inspire Medical Systems, INC. | $76.98 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $72.90 | 2020-2021 | |
| Axonics, INC. | $71.11 | 2024 | Bulkamid |
| E.R. Squibb & Sons, L.L.C. | $70.12 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.94 | 2022 | |
| Amgen INC. | $65.63 | 2022-2025 | Otezla, Repatha, Otezla |
| Mylan Specialty L.P. | $64.60 | 2022-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $57.58 | 2023-2024 | Quviviq |
| Lundbeck LLC | $56.60 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $52.34 | 2019-2020 | |
| Alfasigma USA, INC. | $33.57 | 2020 | |
| Medtronic, INC. | $27.40 | 2024 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $25.47 | 2021 | |
| Dexcom, INC. | $20.88 | 2021 | |
| Shield Therapeutics INC | $20.54 | 2023 | Accrufer |
| Corium, LLC | $20.11 | 2022 | |
| Scilex Pharmaceuticals INC. | $20.08 | 2025 | |
| Corcept Therapeutics | $19.58 | 2024 | Korlym |
| Allergan, INC. | $16.25 | 2020 | |
| Bioventus LLC | $15.15 | 2021 | |
| Medtronic USA, INC. | $11.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 | |
| Medtronic Vascular, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.